samedan logo
 
 
spacer
home > pmps > autumn 2008 > what’s in your wallet?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

What’s in Your Wallet?

Wallets have been used for many years as a convenient means to provide patient samples. They typically contain one or more blister pack, along with compliance pamphlets secured to folding panels. Regardless of their form, wallets usually feature other elements that offer literature, calendars, or other dosing reminders. Many styles feature unique child-resistant and senior-friendly features. Branding and anticounterfeiting are options, too.

Predominantly, wallet-style blister packages are used to enhance patient compliance via written instruction and physical display formatting. The standard blister in a box is the simplest form of compliance packaging. But if someone is looking to elevate compliance, to balance child resistance and senior friendliness more effectively, and to have more billboard space, wallet packaging is a better candidate.

MARKET RECOGNITION

Several wallet-style packages were honoured in the Healthcare Compliance Packaging Council’s Compliance Package of the Year programme...

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gerhard Breu studied at the Interstate University of Applied Sciences of Technology, Buchs, between 1979 and 1983, where he gained a BA in Precision Engineering, followed by an MA in Systems Engineering. In 1983, he founded Adec Robot AG, a company producing flexible robot handling and assembly systems. In 1991, ART was sold to SIG Packaging and in 1994, Gerhard became a member of the SIG Verpackungstechnik management team. He joined Dividella AG as a Manager in 1998, and in 2003, he was appointed CEO of the Pharma Packaging Systems division of Körber AG
spacer
Gerhard Breu
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

European Commission Approves BYANNLI® (6-monthly Paliperidone Palmitate; PP6M) for the Maintenance Treatment of Schizophrenia in Adults

 BYANNLI® (6-monthly paliperidone palmitate; PP6M) is the first long-acting injectable schizophrenia treatment to be approved with a twice-yearly dosing regimen[1] . The approval is based on results from the Route 6 Study, which showed that 92.5 percent of patients treated with PP6M were relapse-free at the end of the 12-month double-blind phase1.  
More info >>

White Papers

Crossing the Blood Brain Barrier (BBB): Which Route to Take?

Aptar Pharma

Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement